Drug Overview

Stelara is an advanced and highly effective medication utilized within the field of Dermatology, belonging to the drug class of Interleukin (IL) inhibitors. Representing a major evolution in systemic treatment, this medication is a potent Biologic designed to treat chronic, immune-mediated skin diseases. Rather than using harsh chemicals to broadly suppress the whole immune system, it acts as a highly precise Targeted Therapy, shutting down the specific inflammatory signals responsible for severe skin plaques.

Below are the essential details regarding this medication:

Generic Name: Ustekinumab
US Brand Names: Stelara (Note: FDA-approved biosimilars such as Wezlana and Selarsdi have also recently entered the market).
Route of Administration: Subcutaneous injection (an injection given into the fatty layer just under the skin) for dermatological uses.
FDA Approval Status: Fully FDA-approved. It received its initial landmark approval in 2009 for moderate to severe plaque psoriasis and has since expanded to include pediatric psoriasis and several other severe autoimmune conditions.

What Is It and How Does It Work? (Mechanism of Action)

Ustekinumab is a highly engineered Smart Drug known as a fully human monoclonal antibody. To understand how it clears severe psoriasis, we must look at the specific chemical messengers that drive the immune system at the cellular level.

In patients with moderate to severe psoriasis, the immune system’s T-cells become hyperactive. This hyperactivity is fueled by an overproduction of two specific signaling proteins (cytokines) called Interleukin-12 (IL-12) and Interleukin-23 (IL-23). Both of these cytokines share a common molecular piece known as the p40 protein subunit. Normally, IL-12 and IL-23 travel through the tissue and dock onto IL-12Rβ1 receptors on the surface of immune cells, setting off an intense inflammatory cascade that forces skin cells to multiply rapidly and pile up into thick, red, scaly plaques.

As a precise Immunotherapy, ustekinumab works by seeking out and binding directly to the shared p40 protein subunit of both IL-12 and IL-23. By physically locking onto this p40 piece, the drug neutralizes the cytokines in the bloodstream and tissue fluids, blocking them from ever docking onto the cell receptors. This breaks the chain of communication, rapidly turning off the inflammatory signaling pathway. Without these chemical signals, the hyperactive T-cells calm down, skin cell turnover normalizes, and the thick psoriasis plaques slowly heal and disappear.

FDA-Approved Clinical Indications

Primary Indication

Moderate to Severe Plaque Psoriasis: Specifically approved for adult and pediatric patients (6 years of age and older) who are candidates for systemic therapy or phototherapy.

Other Approved Uses

Rheumatological: Active Psoriatic Arthritis (PsA) in adults and pediatric patients (6 years and older).
Gastroenterological: Moderately to severely active Crohn’s Disease (CD) in adults.
Gastroenterological: Moderately to severely active Ulcerative Colitis (UC) in adults.

Dosage and Administration Protocols

The following table outlines the standard subcutaneous administration protocol for adults treating moderate to severe plaque psoriasis. Because this is a Targeted Therapy, the dosage is strictly determined by the patient’s body weight.

Dose Adjustments and Special Populations:

Renal or Hepatic Insufficiency: Because monoclonal antibodies are broken down into peptides and amino acids rather than being cleared by the kidneys or liver, no specific dose adjustments are required for patients with renal or hepatic impairment.
Pediatric Population (Ages 6 to 17): The dosage is strictly weight-based. Children weighing less than 60 kg receive 0.75 mg/kg; those weighing 60 kg to 100 kg receive 45 mg; and those over 100 kg receive 90 mg on the standard week 0, week 4, and every 12 weeks schedule.

Clinical Efficacy and Research Results

Ustekinumab is widely celebrated in dermatology for its incredible convenience (requiring only 4 injections per year during maintenance) and exceptional long-term “drug survival” rate. Real-world aggregate data and major clinical studies spanning 2020 through 2026 continue to highlight its potent efficacy.

Current clinical data demonstrates the following:

PASI 75 (75% improvement in skin clearance): Approximately 70% to 75% of patients achieve a PASI 75 response by week 12 of treatment.
PASI 90 (90% improvement or near-complete skin clearance): Roughly 45% to 50% of patients achieve a PASI 90 response, with many maintaining this near-complete clearance long-term.
Long-Term Sustenance: 2023-2025 extension studies confirm that ustekinumab has one of the highest drug survival rates in dermatology. Over 70% of patients who respond to the drug continue to maintain clear skin and stay on the medication beyond 5 years of continuous use, without developing neutralizing anti-drug antibodies that typically cause older Biologics to fail.

Safety Profile and Side Effects

(Note: There is no Black Box Warning for ustekinumab. It is considered one of the safest biologics available for psoriasis.)

Common Side Effects (>10% of patients)

Nasopharyngitis (upper respiratory infections, such as the common cold or sinus infections).
Upper respiratory tract infections.
Headache.
Fatigue.
Mild injection site reactions (redness, pain, or swelling where the needle entered).

Serious Adverse Events

Serious Infections: Increased risk of bacterial, viral, or fungal infections that may require hospitalization (e.g., active tuberculosis, pneumonia).
Malignancies: A slight theoretical increased risk of certain types of skin cancers (non-melanoma) or lymphomas, as the immune system is partially suppressed.
Hypersensitivity Reactions: Anaphylaxis or severe allergic reactions.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): An exceptionally rare neurological condition causing headache, seizures, confusion, and visual disturbances.

Management Strategies

Infection Vigilance: If a severe infection occurs, the Immunotherapy must be paused immediately until the infection is completely treated with appropriate antibiotics or antivirals.
Screening: Physicians must screen all patients for latent Tuberculosis (TB) prior to starting therapy. If latent TB is found, it must be treated with anti-TB medication before the first ustekinumab injection is administered.

Connection to Stem Cell and Regenerative Medicine

While ustekinumab is primarily an immune-suppressing Smart Drug, advanced research in dermatology and gastroenterology (2024-2026) is investigating its intersection with regenerative medicine. One of the greatest hurdles for Mesenchymal Stem Cell (MSC) therapy in treating severe autoimmune diseases is that the patient’s hyperactive, hostile immune environment quickly destroys the introduced stem cells before they can heal the tissue. Current clinical trials are exploring the use of IL-12/23 inhibitors like ustekinumab to “pre-condition” or quiet the immune microenvironment. By neutralizing the aggressive IL-12 and IL-23 cytokines, ustekinumab creates a stable, biologically friendly “runway,” potentially allowing advanced stem cell therapies to successfully engraft, survive, and promote deep tissue regeneration in patients with highly treatment-resistant disease.

Patient Management and Practical Recommendations

Pre-Treatment Tests

Tuberculosis screening (QuantiFERON-TB Gold blood test or PPD skin test).
Baseline Complete Blood Count (CBC) and Comprehensive Metabolic Panel (CMP).
Routine age-appropriate cancer screenings (such as mammograms or colonoscopies) should be up to date before deliberately suppressing the immune system.

Precautions During Treatment

Live Vaccines: Patients must absolutely not receive any “live” or “live-attenuated” vaccines (such as the MMR, yellow fever, or nasal flu vaccine) while on this medication, as the suppressed immune system could allow the vaccine virus to cause an actual infection. Non-live vaccines (like the standard injectable flu shot) are safe and highly recommended.
Symptom Awareness: Be vigilant for unusual symptoms such as a persistent cough, unexpected weight loss, night sweats, or a high fever, which could indicate a hidden infection.

Do’s and Don’ts

DO store your prefilled syringes in the refrigerator (36°F to 46°F / 2°C to 8°C) in their original carton to protect them from light.
DO take the syringe out of the refrigerator and let it sit at room temperature for about 30 minutes before injecting to minimize stinging.
DO rotate your injection sites (alternate between the front of the thighs and the lower abdomen, staying at least 2 inches away from the belly button).
DON’T shake the prefilled syringe. This is a fragile protein Biologic, and vigorous shaking will destroy the medication.
DON’T inject into areas where the skin is tender, bruised, red, hard, or where you currently have active psoriasis plaques.
DON’T freeze the medication. If the syringe has been accidentally frozen, throw it away and contact your pharmacy.

Legal Disclaimer

The information provided in this document is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your physician, dermatologist, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read here.